MeSH tree: N04.761.559.590
Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in patients with advanced non-small ...
Sep 7, 2025
0
36
A new policy review published in The Lancet Oncology and led by Ian Tannock and Madeline Pe, together with an international team of oncologists, statisticians, patients and patient-reported outcomes (PRO) experts from Common ...
Sep 3, 2025
0
12
For the first time in Australia, an independent committee is considering whether Medicare should fund gender-affirming surgery for trans adults (those aged 18 and over).
Aug 31, 2025
0
21
The U.S. Food and Drug Administration has approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP).
Aug 21, 2025
0
9
Thanks to new advances in cancer care, more and more people are surviving cancer, with a projected total of 22.5 million survivors by 2032. The need for proper cancer survivorship care grows with each new case of remission, ...
Aug 13, 2025
0
11
Researchers from the U.K. and Madagascar, in collaboration with Madagascar's health services and national plague program, have conducted the world's first rigorous clinical trial of treatments for bubonic plague.
Aug 7, 2025
0
30
Patient-centricity is often seen as a matter of ethics, something that "should" be done on principle. A white paper demonstrates that patient-centricity is not just an ethical imperative, but strategically essential for digital ...
Jul 31, 2025
0
17
It was during the COVID-19 pandemic—when burnout was hitting the health-care system the hardest—that Sarah Forgie started thinking about joy at work.
Jul 23, 2025
0
17
Amblyopia, commonly referred to as "lazy eye," is the leading cause of vision loss in one eye in children, affecting around 2% of the population. Treatment success varies based on sociodemographic factors, with previous studies ...
Jul 17, 2025
0
15
The National Cancer Center Research Institute in Tokyo reports that a newly isolated gut bacterium, designated Hominenteromicrobium strain YB328, mobilizes specialized dendritic cells to strengthen the impact of PD-1 blockade ...
